The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?
Featured:
Amer ZeidanDuring the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked: What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?
What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?
The STIMULUS program represents a number of clinical trials that are evaluating the anti-TIM-3 checkpoint inhibitor, MBG453, for the treatment of myeloid malignancies. Alternative immune checkpoint inhibitors have demonstrated mixed results, and therefore the TIM-3 pathway is being investigated for therapeutic intervention.
In early phase clinical trials, MBG453 combination regimens exhibited promising clinical activity, prompting the further studies that now comprise the STIMULUS program.